DHA and EPA in Sickle Cell Disease Favor Clinical Improvement and Contribute to Better Quality of Life: A Qualitative Systematic Review.
Jamille da Conceicao SouzaAna Paula Azevêdo MacêdoMariane Dos Santos GonçalvesAdriano de Souza Santos MonteiroCynara Gomes BarbosaFábio David CoutoRicardo David CoutoPublished in: Current drug research reviews (2024)
The findings suggest that n-3 adjuvant therapy favors the clinical and general aspects of people with sickle cell disease.